Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

Anita T. Shaffer and Morgan Meisner, PhD
Published: Wednesday, Jul 17, 2019
Although therapies aimed at BRAF mutations have shown efficacy in several tumor types, these drugs have demonstrated limited success in studies involving patients with colorectal cancer (CRC).1 Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x